Twice is nice. Hemab Therapeutics (COAG) upsized its IPO again at pricing last night – increasing its size to 16.75 million shares – up from 15 million shares earlier in the day – and priced its IPO at $18.00 – the top of its range – to raise $301.5 million on Thursday night, April 30, 2026. The Hemab IPO’s original terms had called for 11.76 million shares at a price range of $16.00 to $18.00.
Hemab Therapeutics shares are set to start trading today – Friday, May 1, 2026 – on the NASDAQ.
At pricing, Hemab Therapeutics had a market cap of $795.47 million.
Goldman Sachs, Jefferies and Evercore ISI were the joint book-runners.
Hemab Therapeutics (COAG), based in Cambridge, Massachusetts, is developing subcutaneous treatments for rare blood coagulation disorders. Its leading product candidate, sutacimig – also known as HMB-001 – has completed Phase 2 trials. It’s ready for Phase 3 trials to treat Glanzmann thrombasthenia and it’s ready for Phase 2 trials to treat Factor VII deficiency. Its therapeutic candidate, HMB-002, is in Phase 1/2 trials for Von Willebrand Disease.
Hemab Therapeutics, based in Cambridge, Massachusetts, is backed by RA Capital.
The company is not profitable: It had a net loss of $63.91 million on no revenue for the year that ended Dec. 31, 2025, according to the prospectus.
(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.